XTL Biopharmaceuticals Ltd. Sponsored ADR (XTLB) has released an update.
XTL Biopharmaceuticals Ltd. has reached a settlement agreement with The Social Proxy Ltd., significantly reducing the number of shares and warrants issued to former shareholders of the acquired company. This adjustment means the former shareholders now hold approximately 20% of XTL’s share capital, while The Social Proxy continues to operate as a wholly owned subsidiary. The resolution includes changes to board representation and the handling of ADS rights, which may interest investors following XTL’s strategic maneuvers in the pharmaceutical and AI sectors.
For further insights into XTLB stock, check out TipRanks’ Stock Analysis page.
